The long-term effects of COVID-19 vaccines, which have protected millions globally, are continually under investigation.Recent comprehensive research conducted in France offers compelling data addressing ongoing discussions surrounding the lasting safety profile of mRNA vaccines. Published on December 4, 2025, in JAMA Network Open, this study provides robust scientific evidence to inform these critical conversations.
Analyzing data from France’s National health Data System, the research revealed that Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines did not elevate the risk of all-cause mortality in adults aged 18 to 59. In fact, the study demonstrated a important reduction in mortality rates among vaccinated individuals. as we move into 2026, understanding these long-term outcomes remains paramount for public health strategies.
A Study of Nearly 28 Million Individuals
Researchers compared 22,767,546 individuals who received their first dose of an mRNA vaccine between May 1 and October 31,2021,with 5,932,443 unvaccinated individuals as of November 1,2021. Participants were monitored for an average of 45 months-approximately four years. The resulting data clearly indicated a higher survival rate within the vaccinated group when contrasted with their unvaccinated counterparts.
Key Findings from the French Study
The analysis yielded several significant findings:
- All-cause mortality risk was 25% lower in vaccinated individuals.
- The risk of death related to COVID-19 decreased by 74% among those vaccinated.
- Even when examining deaths not attributed to COVID-19, the vaccinated group exhibited approximately a 24% lower risk of mortality.
I’ve found that presenting data in this format-clear, concise bullet points-helps readers quickly grasp the core takeaways. It’s about making complex information accessible and actionable.
No Increase in Cancer or Cardiovascular Disease Mortality
importantly, the research found no evidence suggesting that mRNA vaccines increased mortality rates from cancer or circulatory system diseases. indeed, death rates from these causes were also lower in the vaccinated group. This study specifically focused on the 18-59 age group, a demographic often experiencing milder illness and where vaccine necessity is frequently debated.